<DOC>
	<DOCNO>NCT00003183</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy G-CSF may make tumor cell sensitive chemotherapy drug may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness mitoxantrone plus G-CSF treating patient metastatic prostate cancer respond hormone therapy .</brief_summary>
	<brief_title>Mitoxantrone G-CSF Treating Patients With Metastatic Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Study effectiveness mitoxantrone patient metastatic , hormone refractory prostate cancer . II . Assess side effect mitoxantrone patient population . III . Determine whether filgrastim ( granulocyte colony-stimulating factor ; G-CSF ) treatment overcome chronic bone marrow suppression facilitate dose intensive mitoxantrone chemotherapy regimen patient population . OUTLINE : This dose escalation study . Patients receive 30 minute intravenous infusion mitoxantrone week day 1 . On day 2-6 week , patient receive subcutaneous filgrastim ( granulocyte colony-stimulating factor ; G-CSF ) . Treatment continue patient respond therapy exhibit disease progression . Dose escalation proceeds maximum tolerate dose ( MTD ) mitoxantrone G-CSF support determine . The MTD define dose precede 2 patient experience dose limit toxicity . After MTD determine , additional 20-40 patient enrol dose level examine response therapy . PROJECTED ACCRUAL : Approximately 12-24 patient accrued phase I portion protocol . An additional 20-40 patient may accrue phase II portion study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm hormone refractory adenocarcinoma prostate Metastatic disease require PATIENT CHARACTERISTICS : Age : Not specify Performance status : SWOG 02 Life expectancy : Greater 12 week Hematopoietic : Absolute granulocyte count great 1500/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin le 2.0 mg/dL SGOT le 2 time normal Renal : Creatinine le 1.5 mg/dL Cardiovascular : Must adequate cardiac function ( LVEF least 40 % ) Other : No malignancy except skin lesion completely excise No prior hypersensitivity E. coli derive product PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : See Disease Characteristics At least 1 month since LHRH agonist and/or flutamide Radiotherapy : No concurrent radiotherapy No prior extensive radiotherapy ( whole pelvic irradiation ) Surgery : Not specify</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2001</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>